Market Performance of Envveno Medical (NVNO)
During the 24‑hour trading window that concluded at 01:44 AM Central European Time on Friday, 23 December, the shares of Envveno Medical Corp. (NVNO) slipped by 4.81 %. At the close, one share was priced at approximately USD 6.91 on major exchanges. The company’s free float currently totals 683,100 shares, giving it a market capitalisation of USD 5.3 million. In the most recent 24‑hour period, roughly USD 335,000 worth of NVNO stock changed hands.
Contextualising the Decline
- Recent Trajectory: NVNO has fallen 19.45 % since the end of the previous month, underscoring a prolonged downturn that has outpaced many peers.
- Technical Indicators: The 200‑day simple moving average sits at USD 10.49, a level that the current price has breached, signalling a bearish bias. Historically, the stock’s high over the past 52 weeks was USD 26.70 (24 October 2025), while the low reached USD 7.01 (16 September 2026), highlighting the recent contraction toward the lower end of its range.
- Liquidity: With USD 335 k traded in the last day, liquidity remains moderate. The limited volume may amplify price swings, especially during after‑hours sessions.
Comparison With Peer Performances
The broader sector has delivered mixed results in the same 24‑hour window:
| Stock | Symbol | % Change | Current Price (USD) | Market Cap (USD) |
|---|---|---|---|---|
| Acurx | ACXP | +0.88 % | 1.14 | 6 million |
| Processa | PCSA | –1.68 % | 1.86 | 6 million |
| Advanced Biomed | ADVB | –1.05 % | 3.46 | 6.3 million |
| Moleculin Biotech | MBRX | +1.94 % | 5.89 | 6 million |
| Alzamend Neuro | ALZN | –3.85 % | 1.12 | 6.3 million |
While a handful of peers, notably Moleculin Biotech, experienced gains, the majority of comparable companies mirrored the downward trend seen in NVNO. This pattern suggests that the pressure on NVNO is not isolated but may reflect sector‑wide sentiment or broader market volatility.
Company Overview
Envveno Medical Corp. is a medical‑device company headquartered in Irvine, California, that focuses on bioprosthetic, tissue‑based solutions for venous disease. The firm’s product line is designed to elevate the standard of care for patients suffering from venous disorders, offering minimally invasive alternatives that leverage living tissue. NVNO is listed on the Nasdaq stock exchange and maintains a digital presence through its website at www.envveno.com .
The information above reflects the most recent market activity and fundamental data available for Envveno Medical and its peers. Investors should conduct their own due diligence before making investment decisions.
